or Try an Advanced Search...

    Technical Analysis for GNLX - Genelux Corporation

    Grade Last Price % Change Price Change
    F 1.84 -5.64% -0.11
    GNLX closed down 5.64 percent on Monday, July 1, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GNLX trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -5.64%
    180 Bearish Setup Bearish Swing Setup -5.64%
    Volume Surge Other -5.64%
    Older End-of-Day Signals for GNLX ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 5 hours ago
    Possible NR7 about 6 hours ago
    2x Volume Pace about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    1.5x Volume Pace about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GNLX Chart by TradingView
    Basic chart:

    Profile

    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer

    Is GNLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 24 Genelux 6.875M share Spot Secondary priced at $4
    May 24 Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop
    May 24 Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
    May 23 Genelux announces proposed public offering of common stock and warrants
    May 23 Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
    May 10 Genelux GAAP EPS of -$0.29 misses by $0.06
    May 9 Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
    May 5 Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
    Apr 26 Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
    Apr 23 Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
    See more GNLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 35.15
    52 Week Low 1.84
    Average Volume 296,681
    200-Day Moving Average 10.33
    50-Day Moving Average 3.08
    20-Day Moving Average 2.33
    10-Day Moving Average 2.18
    Average True Range 0.30
    RSI (14) 31.03
    ADX 26.99
    +DI 11.69
    -DI 28.19
    Chandelier Exit (Long, 3 ATRs) 1.93
    Chandelier Exit (Short, 3 ATRs) 2.74
    Upper Bollinger Bands 2.76
    Lower Bollinger Band 1.89
    Percent B (%b) -0.06
    BandWidth 37.38
    MACD Line -0.35
    MACD Signal Line -0.36
    MACD Histogram 0.0102
    Fundamentals Value
    Market Cap 49.16 Million
    Num Shares 26.7 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -1.74
    Price-to-Sales 1003.60
    Price-to-Book 10.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.17
    Resistance 3 (R3) 2.21 2.13 2.12
    Resistance 2 (R2) 2.13 2.05 2.12 2.10
    Resistance 1 (R1) 1.99 2.00 1.95 1.95 2.08
    Pivot Point 1.91 1.91 1.90 1.90 1.91
    Support 1 (S1) 1.77 1.83 1.73 1.73 1.60
    Support 2 (S2) 1.69 1.78 1.68 1.58
    Support 3 (S3) 1.55 1.69 1.57
    Support 4 (S4) 1.51